Mumbai: Sanofi Consumer Healthcare India Ltd. has announced the company's Q1 results with Profit After Tax (PAT) at Rs 500 ...

Analysts anticipate Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.31. Anticipation surrounds Vertex Pharmaceuticals's announcement, with investors hoping to hear about both ...

MML Investors Services ramped up its Regeneron stake by 41.7%, acquiring 2,218 additional shares during Q4. This brings their ...

Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...